HLB Pharmaceutical Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 11.61%

HLB Pharmaceutical Co. Ltd (047920) has an Asset Resilience Ratio of 11.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of HLB Pharmaceutical Co. Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩19.49 Billion

≈ $13.21 Million USD Cash + Short-term Investments

Total Assets

₩167.93 Billion

≈ $113.80 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how HLB Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See 047920 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down HLB Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of HLB Pharmaceutical Co. Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩19.49 Billion	11.61%
Total Liquid Assets	₩19.49 Billion	11.61%

Asset Resilience Insights

Moderate Liquidity: HLB Pharmaceutical Co. Ltd has 11.61% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

HLB Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare HLB Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for HLB Pharmaceutical Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	13.92%	₩21.99 Billion ≈ $14.90 Million	₩157.93 Billion ≈ $107.03 Million	-4.38pp
2023-12-31	18.30%	₩25.87 Billion ≈ $17.53 Million	₩141.35 Billion ≈ $95.79 Million	+0.99pp
2022-12-31	17.32%	₩24.62 Billion ≈ $16.69 Million	₩142.18 Billion ≈ $96.35 Million	-2.69pp
2021-12-31	20.01%	₩25.54 Billion ≈ $17.31 Million	₩127.63 Billion ≈ $86.49 Million	-51.12pp
2020-12-31	71.13%	₩79.25 Billion ≈ $53.71 Million	₩111.42 Billion ≈ $75.51 Million	+40.87pp
2019-12-31	30.25%	₩14.04 Billion ≈ $9.51 Million	₩46.39 Billion ≈ $31.44 Million	+21.30pp
2018-12-31	8.95%	₩3.26 Billion ≈ $2.21 Million	₩36.42 Billion ≈ $24.68 Million	-5.79pp
2017-12-31	14.74%	₩5.87 Billion ≈ $3.98 Million	₩39.85 Billion ≈ $27.00 Million	-14.17pp
2016-12-31	28.91%	₩11.92 Billion ≈ $8.08 Million	₩41.24 Billion ≈ $27.95 Million	+27.30pp
2015-12-31	1.61%	₩399.39 Million ≈ $270.66K	₩24.85 Billion ≈ $16.84 Million	-8.95pp
2014-12-31	10.56%	₩2.26 Billion ≈ $1.53 Million	₩21.43 Billion ≈ $14.53 Million	--

pp = percentage points

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$267.62 Million

₩394.90 Billion KRW

Market Cap Rank

#15492 Global

#540 in Korea

Share Price

₩12040.00

Change (1 day)

+9.85%

52-Week Range

₩10710.00 - ₩20900.00

All Time High

₩41100.00